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iabetes is the leading cause of
chronic kidney disease (CKD) and
is associated with excessive cardio-
vascular morbidity and mortality (1,2).
Anemia is common among those with di-
abetesandCKDandgreatlycontributesto
patient outcomes (3,4). Observational
studiesindicatethatlowHblevelsinsuch
patients may increase risk for progression
ofkidneydiseaseandcardiovascularmor-
bidity and mortality (5). Controlled clin-
ical trials of anemia treatment with
erythropoietin stimulating agents (ESAs)
demonstrated improved quality of life
(QOL) but have not demonstrated im-
proved outcomes (6–10). In some trials,
ESA treatment for high Hb levels is asso-
ciated with worse outcomes such as
increased thrombosis risk (6,11). Con-
sequently, the U.S. Food and Drug Ad-
ministration (FDA) and the National
Kidney Foundation (NKF) have modiﬁed
their recommendations regarding anemia
treatment for CKD patients (12). The ob-
jectives of this review are to 1) update cli-
nicians on the prevalence, causes, and
clinical consequences of anemia; 2) dis-
cuss the beneﬁts and risks of treatment;
and 3) provide insight into anemia man-
agementbasedonclinicaltrialevidencein
patients with diabetes and kidney disease
who are not on dialysis.
DEFINITION AND
PREVALENCE OF ANEMIA
IN CKD— The NKF deﬁnes anemia in
CKD as an Hb level 13.5 g/dl in men
and 12.0 g/dl in women (13). This deﬁni-
tion is based on the fact that these levels
are outside the 95% CIs of the mean for
normal men and women. Anemia is com-
mon in diabetic patients with CKD (5). It
is estimated that one in ﬁve patients with
diabetes and stage 3 CKD have anemia,
and its severity worsens with more ad-
vanced stages of CKD and in those with
proteinuria (7,14,15) For example, in a
5-year prospective observational study
conducted in a diabetes clinic in Austra-
lia, anemia was found in early kidney dis-
ease, and declining Hb levels were more
common among those with higher levels
of albuminuria (16) The distribution of
Hb in patients with diabetes and CKD is
similar to that in those without diabetes,
but on average, Hb levels are lower. For
these reasons, it is recommended that cli-
nicians measure serum creatinine and
urine albumin and creatinine to estimate
glomerular ﬁltration rate (GFR) and iden-
tify and quantitate albumin excretion rate
in patients with diabetes and anemia
patients.
CAUSES OF ANEMIA— Anemia
in diabetic patients with CKD may result
from one or more mechanisms. Vitamin
deﬁcienciessuchasfolateandB12arerel-
atively uncommon, and clinical practice
guidelines do not recommend routine
measurement of these serum levels. (See
below.) The major causes of anemia in
CKD patients are iron and erythropoietin
deﬁciencies and hyporesponsiveness to
the actions of erythropoietin.
Iron deﬁciency
Iron deﬁciency in the general population
is a common cause of anemia and is prev-
alent in patients with diabetes and CKD.
In these same patients, dietary deﬁciency,
low intestinal absorption, and gastroin-
testinal bleeding may result in absolute
iron-deﬁciency anemia. Recent analyses
of the National Health and Nutrition Ex-
amination Survey IV suggest that up to
50%ofpatientswithCKDstages2–5have
absolute or relative (functional) iron deﬁ-
ciency (17). In CKD, both absolute and
relative iron deﬁciency are common. Ab-
solute iron deﬁciency is deﬁned as a de-
pletionoftissueironstoresevidencedbya
serum ferritin level 100 ng/ml or a
transferrin saturation of 20%. Func-
tional iron deﬁciency anemia is adequate
tissueirondeﬁnedasaserumferritinlevel
100 ng/ml and a reduction in iron sat-
uration.Thelatterismorecommonandis
strongly associated with upregulation of
inﬂammatory cytokines and impaired tis-
sue responsiveness to erythropoietin,
which can inhibit iron transport from tis-
sue stores to erythroblasts (18). Increased
levels of inﬂammatory cytokines such as
interleukin-6enhanceproductionandse-
cretion of hepcidin, a hepatic protein that
inhibitsintestinalironabsorptionandim-
pairs iron transport from the reticuloen-
dothelial system to bone marrow. In
addition, erythropoietin, which normally
enhances iron transport from macro-
phages to the blood stream, is impaired,
thereby exacerbating relative iron deﬁ-
ciency (19).
Erythropoietin deﬁciency and
hyporesponsiveness
Both deﬁciency and hyporesponsiveness
to erythropoietin contribute to anemia in
diabetic patients with CKD (15,20). The
cause of erythropoietin deﬁciency in
these patients is thought to be reduced
renal mass with consequent depletion of
the hormone. Hyporesponsivness is de-
ﬁned clinically as a requirement for high
doses of erythropoietin in order to raise
blood Hb level in the absence of iron de-
ﬁciency.Itisbelievedtorepresentimpaired
antiapoptotic action of erythropoietin on
proerythroblasts. Possible causes of this
erythropoietin hyporesponsiveness include
systemic inﬂammation and microvascular
damage in the bone marrow (15,20). How-
ever,somestudiessuggestthatotherfactors
(i.e., autonomic failure) may play a role in
impaired erythropoietin production or se-
cretion by failing kidneys (21).
Nephrotic syndrome
Nephrotic syndrome characterized by
edema, hypoalbuminemia, dyslipidemia,
and urine protein-to-creatinine ratio 3
is not uncommon in patients with dia-
betic nephropathy and can occur even in
early stages of CKD (e.g., stages 1–2)
(21,22). The mechanism of anemia in ne-
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volves both inﬂammatory-mediated
mechanisms as discussed above as well as
absolute iron deﬁciency. Iron excretion
increases in early stages of kidney disease
inpatientswithdiabetesandalbuminuria
and is exacerbated by development of ne-
phrotic-range proteinuria. In nephrotic
syndrome, many nonalbumin proteins
are excreted in the urine, including trans-
ferrin and erythropoietin. Signiﬁcant
losses of transferrin and erythropoietin
canoccurinnephroticsyndrome,leading
to both iron- and erythropoietin-
deﬁciency–caused anemia in patients
with diabetes (23). Evidence for in-
creased transferrin catabolism in ne-
phrotic syndrome may contribute to
iron deﬁciency–caused anemia (24).
Decreased erythropoietin production,
secretion, and hyporesponsiveness can
contribute to anemia in nephrotic pa-
tients. (See above.)
ACE inhibitors and angiotensin
receptor antagonists
Both of these drug classes may cause a
reversible decrease in Hb concentration
in patients with diabetes and CKD (25).
The mechanisms by which ACE inhibi-
tors and angiotensin receptor blockers
lower Hb include a direct blockade of the
proerythropoietic effects of angiotensin II
on red cell precursors, degradation of
physiologicalinhibitorsofhematopoiesis,
and suppression of IGF-I. Long-term ad-
ministration of losartan in 50- to 100-mg
doses once daily in patients with diabetes
and albuminuria is expected to lower Hb
by 1 g/dl. Importantly, this effect does
not diminish the renoprotective effect of
losartan. It should be recognized that
these classes of agents may induce or
worsen symptomatic anemia in nephrop-
athy patients (26).
CONSEQUENCES OF
ANEMIA
Quality of life
Anemia is an important cause of physical
and mental impairments in diabetic CKD
patients including malaise, fatigue, weak-
ness, dyspnea, impaired cognition, and
other symptoms. Clinical trials indicate
that improving anemia improves cogni-
tive function, sexual function, general
well-being, and exercise capacity and re-
duces the need for blood transfusions
(6,8–10,27) There is renewed evidence
of anemia in diabetes contributing to
retinopathy,neuropathy,diabeticfootul-
cer, hypertension, progression of kidney
disease, and cardiovascular events (15).
Progression of kidney disease
In general, kidney disease in diabetes is
progressive, and it has been hypothesized
that anemia may contribute to progres-
sion of kidney disease (7,16,28,29). Pos-
sible mechanisms include renal ischemia
causedbyreducedoxygendeliverydueto
low Hb and underlying heart failure. For
example, anemia may worsen renal med-
ullaryhypoxia,leadingtorenalinterstitial
injuryandﬁbrosis(30,31).Wholeanimal
and in vitro studies indicate that renal
hypoxia upregulates hypoxia-inducible
factor-1, a transcriptional regulator of
the erythropoietin gene as well as heme
oxygenase, nitric oxide synthases, extra-
cellular matrix, and apoptosis genes. It is
upregulatedbyrenalhypoxiaandinduces
collagen gene expression in renal ﬁbro-
blasts, thereby increasing interstitial ﬁ-
brosis. Anemia may also increase renal
sympathetic nerve activity, resulting in
increased glomerular pressure and pro-
teinuria (which in turn may accelerate
progression of kidney disease), and con-
tribute to worsening kidney function by
exacerbating underlying heart failure—a
common complication in patients with
diabetes and kidney disease, (29).
Early animal model studies in renal
ablation, hypertension, and diabetes
demonstrated that treatment of anemia
worsened systemic and glomerular hy-
pertension and renal structural and func-
tional damage, suggesting that anemia
may actually be renoprotective (32,33).
Recently, Nakamura et al. (34) demon-
strated that administration of an erythro-
poietin-stimulating agent to patients with
anemia and CKD decreased urine fatty
acid–binding protein—a molecule known
to be associated with increased risk for
kidney disease progression—suggesting
that ESA may have a renoprotective effect
independent of Hb level. However, in
clinical trials, erythropoietin has not yet
been proven to slow kidney disease pro-
gression in patients with diabetes and ne-
phropathy. (See below.)
Cardiovascular disease
Observational studies indicate that death
is ﬁve times more likely than progression
to end-stage kidney disease in patients
with CKD (35). Moreover, cardiovascular
disease is the most common cause of
death in patients with diabetes and CKD;
andanemiaappearstobeariskmultiplier
for all-cause mortality among those same
patients. Anemia prevalence is up to 10-
fold higher among diabetic patients with
CKD and heart failure and is a modiﬁable
risk factor among diabetic patients (36,
37).LowHbconcentrationisanindepen-
dent risk factor for left-ventricular hyper-
trophy, heart failure, and cardiovascular
mortality (37–44). Heart failure is com-
mon in diabetic patients with nephropa-
thyandmayresultinreducedrenalblood
ﬂow, thereby contributing to further re-
duction in GFR and erythropoietin pro-
duction. Also, anemia may aggravate
tissue hypoxia, and subsequently heart
failure, resulting in further renal sodium
retention, volume expansion, increased
venous return, and increased venomotor.
For these reasons, treatment of anemia in
patients with diabetes and CKD is a pro-
posedstrategytoreduceexcessivecardio-
vascular morbidity and mortality. (See
below.)
CLINICAL TRIALS OF
ERYTHROPOIETIN-
STIMULATING AGENTS—I ti s
important to note that none of the pub-
lished trials examining the safety and ef-
ﬁcacy of ESA for anemia treatment
included a placebo control group. With
one exception (45), all study subjects
(withvaryingHblevels)weretreatedwith
an ESA.
RENAL OUTCOMES— Several small
trials in patients with CKD, including
those with diabetes, demonstrated a ben-
eﬁcial effect on kidney disease progres-
sion. Kuriyama et al. (45) studied 106
patients with stage 3–4 CKD with or
without anemia. Those with anemia were
randomized to ESA treatment or no treat-
ment. The time to a doubling of serum
creatinine from baseline was the study’s
primary end point. They found that time
to doubling of serum creatinine was sig-
niﬁcantlylongerinthetreatedgroupthan
in the nontreated group and similar to
that in the nonanemic control subjects
(45). Gouva et al. (46) randomized 88
anemic stage 3–5 CKD patients to early
versus late treatment with erythropoie-
tin- to test the hypothesis that this
intervention would slow the rate of pro-
gression to end-stage renal disease
(ESRD). They found that early correction
of anemia was associated with improved
renal and patient survival compared with
delayedtreatmentofanemia.Rossertetal.
performed a randomized controlled trial
involving 390 patients with stage 3–4
CKD and anemia to test the hypothesis
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reach a higher Hb level would slow de-
cline in kidney function. Subjects were
targetedtooneoftwoHblevels(13–15or
11–12 g/dl) and followed for 12 months.
Although the decline in GFR was numer-
ically less in the high-Hb group, this dif-
ference was not statistically signiﬁcant.
Still, those randomized to the high group
showedimprovementinQOLandvitality
(47). However, the two largest trials to
date to examine the effect of ESA on pro-
gression of kidney disease (as a secondary
outcome) did not show any renal beneﬁt
of raising Hb to a higher level. (See
below.)
CARDIOVASCULAR
OUTCOMES— Roger et al. (9) con-
ducted a prospective, randomized, open-
label trial in 155 anemic CKD patients
(stage 3–4), testing the hypothesis that
ESA treatment could prevent develop-
ment or progression of left-ventricular
hypertrophy. Study subjects were ran-
domized to receive subcutaneous dosing
with erythropoietin- to achieve and
maintain Hb in the range of 9–10 or
11–13 g/dl and followed for 2 years with
repeated measures of left-ventricular
structure and function. They found no
difference in the primary outcome of left-
ventricular wall thickness; however,
thoseassignedtothehigherHbarmofthe
study experienced improvement in QOL.
Levin et al. (8) conducted a randomized
clinical trial to test the hypothesis that
prevention or correction of anemia, by
immediate versus delayed treatment with
erythropoietin- in patients with CKD,
would delay or prevent left-ventricular
hypertrophy. The primary outcome was
the change in left-ventricular mass index.
They randomized 176 CKD patients who
hadexperiencedadecreaseof1g/dlHbin
the prior year and a baseline Hb level of
11–13.5 g/dl to treatment with epoetin-
to maintain Hb in the range of 12–14 g/dl
ortomaintainatargetHbrangeof9–10.5
g/dl; the subjects were followed for 24
months with repeated measures of left-
ventricular structure and function. De-
spite signiﬁcant difference in Hb level
between groups, they found no signiﬁcant
difference in left-ventricular mass index.
Those assigned to higher Hb experienced
improvement in QOL (Table 1).
Ritzetal.randomized172anemicpa-
tients with type 1 or type 2 diabetes and
stage 1–3 CKD to treatment with epo-
etin- and a target Hb level of either
13–15 or 10.5–11.5 g/dl and followed
them for 19 months. The primary out-
come was the change in left-ventricular
mass index, and secondary outcomes in-
cluded kidney function and QOL. There
were no signiﬁcant differences in left-
ventricular mass index in those random-
ized to the higher target; however, QOL
measures were signiﬁcantly better in the
higherHbarm.Therewerenodifferences
in kidney function decline and no signif-
icant differences in adverse events (48).
CARDIOVASCULAR
EVENTS— Singh et al. (11) tested the
hypothesis that a higher Hb level would
reduce risk for the composite cardiovas-
cular outcome of stroke, myocardial in-
farction, heart failure, and all-cause
cardiovascular mortality among patients
with various causes of CKD including di-
abetes (46%). In this trial, the Correc-
tion of Hb and Outcomes in Renal
Insufﬁciency (CHOIR) trial, 1,432 pa-
tients with anemia and stage 3–4 CKD
were randomized to an Hb target of 11.5
or 13–13.5 g/dl and followed for an aver-
age of 16 months (11). During the trial,
Hb levels were signiﬁcantly higher in
those randomized to the higher Hb arm.
The composite event rate was higher in
those assigned to the higher Hb arm;
however, there was no difference in the
rate of development of ESRD. Also, in
contrast to the results of other studies,
there was no improvement in QOL in
those randomized to the higher target.
Theauthorsconcludedthatuseofatarget
Hblevelof13.5g/dl(comparedwith11.3
g/dl) was associated with increased risk
and no incremental improvement in
QOL.Posthocanalysisdemonstratedthat
a higher fraction of patients in the higher
Hbarmhadpriorcoronaryevents,hyper-
tension, and dropout prior to an event or
completion of the study. In the Cardio-
vascular risk Reduction by Early Anemia
Treatment with Epoetin beta (CREATE),
Druekeetal.(6)randomized603patients
with stage 3–4 CKD, from various causes
including diabetes (25%), to early ver-
sus late treatment with epoetin- to test
the hypothesis that a higher Hb level
would reduce risk for cardiovascular
morbidity and mortality. Subjects were
randomized to an Hb target range of 11–
11.5 or 13–15 g/dl and followed for an
average of 36 months. They found no sig-
niﬁcant differences in the primary com-
posite outcome, but there was a trend
toward a higher event rate in the higher
Hb arm. In addition, multiple QOL mea-
suresweresigniﬁcantlyimprovedinthose
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trast to the CHOIR study, the time to
ESRD, a secondary outcome, was shorter
in the higher Hb arm. Post hoc analysis
demonstrated that the study was under-
powered to detect a difference in the pri-
mary outcome variable as a result of the
lower-than-expected overall event rate in
both arms of the study.
The increased risk for adverse out-
comes during ESA treatment of anemia
in clinical trials of patients with CKD is
not completely understood. One possi-
bility is that higher Hb increases risk for
thrombosis. Another possibility is that
those who experience adverse cardio-
vascular events have higher comorbidity,
are relatively resistant to erythropoietin,
and require higher doses of ESA to
achieve higher Hb and that the higher
doses of ESA are vasculotoxic (49). Fur-
ther studies are needed to determine
whether higher doses versus resistance to
action of ESA cause harm in anemic pa-
tients with CKD. The Trial of Reduction
of End points with Aranesp Therapy
(TREAT) is an ongoing large-scale, ran-
domized, double-blind, and placebo-
controlled study including 4,000 anemic
patients with type 2 diabetes and CKD
(50).Theprimaryoutcomeisacomposite
of all-cause mortality and cardiovascular
morbidity. This ongoing trial is unique in
many respects, including the double-
blind, placebo-controlled design; the
population of exclusively anemic patients
withtype2diabetesandCKD;andalarge
sample size. This study will add impor-
tant new information concerning beneﬁts
and risks of ESA treatment of anemia in
patients with diabetes and CKD. Results
are expected in 2010.
In summary, two clear messages
emerge from the anemia treatment trials.
1) Treating patients to achieve a higher
comparedwithalowerHbtargettypically
improves QOL. 2) Treatment to reach a
higher Hb level does not reduce risk for
cardiovascular events and may cause
harm.
CLINICAL PRACTICE
GUIDELINES FOR
EVALUATION OF ANEMIA — The
NKF clinical practice guidelines for diag-
nosis and management of anemia in pa-
tients with CKD recommend a routine
history and physical examination, a com-
plete blood count, a reticulocyte count,
evaluation of serum iron and total iron
binding capacity and serum ferritin level,
and a fecal test for occult blood for eval-
uationofanemia(13,51).Additionaltests
to evaluate anemia should be guided by
this initial evaluation (e.g., serum folic
acid, vitamin B12 level, Coombs test,
etc.). Despite the high prevalence of ane-
mia in the CKD population, treatment
with erythropoietin or iron often is not
used in the predialysis period. For exam-
ple, nearly 70% of patients initiated on
dialysis are anemic by the NKF deﬁnition
but are not treated with erythropoietin,
and 50% of these patients have severe
anemia (hematocrit 30%).
RECOMMENDATIONS FOR
TREATMENT OF ANEMIA
NKF clinical practice guidelines
The NKF currently recommends that
when treating anemia in CKD with an
ESA,theHbtargetrangeshouldbe11–12
g/dl and should not exceed 13 g/dl (51).
In addition, the NKF recommends that
treatment should be individualized, tak-
ingintoaccountpatientcharacteristicsin-
cluding symptoms, Hb level, and
evaluation for other causes of anemia.
(See above.) If the initial evaluation indi-
cates absolute iron deﬁciency as the
cause, treatment with supplemental iron
and a search for the cause of iron loss
shouldbeundertaken.Ifabsoluteironde-
ﬁciency is not present and causes other
than kidney disease are excluded, then
treatment with an ESA should be admin-
istered at a dose sufﬁcient to increase Hb
within the target range of 11–12 g/dl. Im-
portantly,ESA-treatedpatientsshould,in
general, receive iron to ensure that ade-
quate stores are available for erythropoi-
etic response (51). The NKF notes that
with few exceptions, anemia treatment
trials in CKD patients demonstrated that
treatment with an ESA to achieve Hb val-
ues in the range of 11–13 g/dl is associ-
ated with improved QOL.
Food and Drug Administration
Inearly2007,theFoodandDrugAdmin-
istration (FDA) promulgated new recom-
mendations for use of ESA in patients
with CKD, advising them that ESA can
increase risk for heart attack, stroke,
blood clots, heart failure, and death when
given to maintain higher Hb (52). Drugs
affected by their recommendation in-
cluded epoetin- and darbepoetin. The
FDA advised practitioners to use the low-
est dose of an ESA needed to avoid blood
transfusion, targeting blood Hb in the
range of 10–12 g/dl, and to withhold the
dose of ESA when Hb level exceeds 12
g/dl. Manufacturers of ESA accordingly
added black box warnings noting these
recommendations (53).
In summary, the NKF and FDA rec-
ommendations are in conﬂict. Whereas
there is agreement that ESAs are valuable
for treating anemia, they differ with re-
gard to the level of Hb at which to initiate
ESA and the upper limit of the Hb target.
The NKF supports the safety of ESA use
andrecognizestheimportanceofindivid-
ualizing anemia treatment. Further stud-
iesonthesafetyofESAuseinthediabetes
population, as well as efforts to better un-
derstand the explanation for the associa-
tionofhigherHbwithworsecardiovascular
outcomes reported in clinical trials, are
needed.
ANEMIA MANAGEMENT— The
ﬁrst step in the management of anemia is
evaluating the underlying cause. (See
above on diagnosis and evaluation.) If ab-
solute iron deﬁciency is present, the pa-
tient should be put on oral or intravenous
iron therapy. Several oral iron prepara-
tionsareavailablefortreatmentincluding
ferrous gluconate, fumarate, and sulfate.
Doses of 300–325 mg of one of these
agents three times daily can increase the
Hb level signiﬁcantly in such patients.
Notably, signiﬁcant gastrointestinal side
effects may lead to poor adherence and
compliance with oral iron. An alternative
is to administer intravenous iron on a pe-
riodic basis. Several studies indicate that
thesepreparationsareeffectiveandsafein
predialysis populations (11,54,55). Dah-
dah et al. (54) administered intravenous
irondextrantoanemic,iron-deﬁcient(se-
rum ferritin 100 ng/ml or transferrin
saturation 20%) patients with an esti-
mated GFR 50 ml/min and not on dial-
ysis in doses of either 200 mg/week for 5
weeks or 500 mg/week for 2 weeks. Sig-
niﬁcantincreasesinHboccurredwithin2
weeks; all patients tolerated infusions
without serious adverse reactions. Intra-
venous iron preparations including ferric
sodium gluconate, iron sucrose, and iron
dextran are available and can be adminis-
tered safely. Among these agents, iron
dextran has been associated with the
highest incidence of adverse reactions, al-
though the incidence of such reactions is
low with all three preparations. Although
some studies indicate that intravenous
iron is in general more efﬁcacious than
oral iron for achieving increases in Hb in
patients with CKD, oral iron is also effec-
tive (55). Moreover, no deﬁnite advan-
tages have been shown with intravenous
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on dialysis (56).
An initial dose of 10,000 units epoetin-
onceweeklyor0.75g/kgdarbepoetin-
everyotherweeksubcutaneouslyareeffec-
tive for increasing Hb concentration by
1–2 g/dl over 4–8 week periods (27).
Darbepoetin can be administered subcu-
taneously every other week at outset and
thenadministeredoncemonthlytomain-
tain Hb target. Ling et al. (57) demon-
strated efﬁcacy of maintaining Hb in the
range of 10–12 g/dl (total dose of 88 g)
after extending the dosing interval from
every other week to once every 4 weeks.
Provenzano et al. (58) found that an in-
creased dosing interval from weekly to
once monthly using epoetin- in doses
up to 40,000 units maintained Hb in a
similar range.
Extended dosing of short- and long-
acting ESA, including the hematopoietic
and adverse effects, has recently been re-
viewed (59). Currently, the only ESA ap-
proved by the FDA for extended interval
dosingisdarbepoetin.Inclinicalpractice,
darbepoetin is often administered every
other week initially, until the Hb target
is achieved, before extending dosing to
every 4 weeks. Extended dosing may
require an increase in dose (27,57).
Monitoring response to treatment
Patientsshouldbeevaluatedforimprove-
ment in symptoms including fatigue, vi-
tality, physical functioning, and cognitive
function. Initially, Hb level should be
measured every other week to monitor
the hematopoietic response and monthly
thereafter. In general, if an Hb level devi-
ates from the target range (see above), the
dose of the ESA should be adjusted either
upward or downward by 25%. In most
patients, increases or decreases in ESA
dose should not be made more frequently
than monthly. Also, for safety reasons, if
Hb is rising at a rate of 1 g/dl within a
4-week period, the dose should be held,
asmorerapidincreasesmaybeassociated
with increased risk for adverse events
such as hypertension.
Functional iron deﬁciency should be
suspected in any patient not responding
toESAtreatment,andpatientcompliance
with iron therapy should be investigated.
Routine measurement of iron stores in-
cluding serum iron, iron binding capac-
ity, and ferritin should be monitored
monthlyfor3monthsthenquarterlyonce
Hb target is achieved (56,60).
Adverse side effects of therapy
In clinical trials, up to 25% of patients
experience an increase in blood pressure
or develop overt hypertension (blood
pressure 140/90 mmHg) (8,27,47,61–
63).Thus,ESAshouldnotbeusedtotreat
anemia in patients with uncontrolled
blood pressure. Moreover, increases in
blood pressure should be looked for in
any anemic CKD patient treated with an
ESA, and dose adjustments in ESA, iron,
or antihypertension medications should
be undertaken as needed. Common side
effects include local pain or tissue reac-
tion to subcutaneous injection and devel-
opment of ﬂu-like symptoms within
hoursordaysofadministrationofanESA.
A rare but serious form of pure red
cell aplasia can occur during ESA treat-
ment,includinginthosetreatedwithepo-
etinanddarbepoetin(64,65).Theanemia
is sudden in onset and can occur as early
as 2 months after initiation of treatment.
Asnotedabove,ESAmayincreaseriskfor
death and cardiovascular events and
thrombotic events. The risk is reported in
those with Hb levels 12 g/dl in some
clinical trials. Therefore, it is prudent to
modifythedoseofESAtoreducethelike-
lihood of excursions of Hb exceeding 13
g/dl as recommended by the NKF (51).
Adverse effects of iron use are described
aboveandincludegastrointestinalsideef-
fects with oral preparations and anaphy-
lactic reactions with intravenous
preparations.
AREAS OF
UNCERTAINTY— Analysis of avail-
able evidence from clinical trials clearly
indicates that there is enough uncertainty
regardingtherisk-to-beneﬁtratiooftreat-
mentofanemicCKDpatientswithESAto
warrant additional major randomized
clinical trials (66). TREAT is an ongoing
study that will provide additional new in-
formation on whether treatment per se
can improve cardiovascular outcomes in
patientswithtype2diabetes,anemia,and
CKD (50). Because nearly 50% of new
casesofESROintheU.S.areattributedto
diabetes, further studies are needed to
help guide management of anemia. Areas
of uncertainty that remain include estab-
lishment of the optimal individual Hb
level—the level at which patient QOL is
maximized and morbidity and mortality
risks are minimized. The optimal dose of
a given ESA, the frequency of dosing, and
theindicationandtargetHbrangeremain
controversial. For example, should ESA
dosing begin at an Hb level of 10, 11, or
12 g/dl? Another area of uncertainty con-
cerns the diagnosis and management of
erythropoietin hyporesponsiveness, for
which there is no widely accepted, stan-
dardized deﬁnition. This confounds the
analysis of clinical trials in which higher
doses of ESA and higher Hb occur in
those randomized to higher Hb targets.
Additional studies are needed to under-
stand the nature and extent of hypo-
responsiveness to erythropoietin in
patients with CKD—an area of high pri-
ority for future research. However, it is
not established whether the beneﬁts of
improved QOL measures outweigh the
risks of cardiovascular morbidity and
the economic costs related to treatment
to achieve a higher Hb level. Another
area of uncertainty related to hypo-
responsiveness is the role of iron use in
treating anemia. New research that pro-
vides a better understanding of the role
of inﬂammation in iron metabolism,
utilization, and the response to ESA
treatment is another important research
priority.
SUMMARY— Anemia is common
and contributes to both poor QOL and
increased risk for adverse outcomes in-
cluding death. Treatment of anemia im-
proves QOL; however, thus far, evidence
is lacking for a beneﬁt of anemia treat-
ment on progression of kidney disease
and cardiovascular outcomes. The NKF
recommends that physicians consider
treating anemia in patients with diabetes
and kidney disease when Hb is 11 g/dl
in patients. Further, they recommend a
Hb target of 11–12 g/dl, not to exceed 13
g/dl, when using an ESA as part of the
therapeutic regimen for managing ane-
mia. Currently available ESA combined
with iron supplementation can be used
safely and effectively to achieve this goal.
However, available clinical trial evidence
leavessufﬁcientuncertaintyregardingthe
optimal Hb target and ESA dose for a
givenindividual.Forthisreason,theNKF
recommendsindividualizingtreatmentof
anemia with ESA. Additional randomized
clinicaltrialsareneededtomoreprecisely
deﬁne these parameters for an individual
patient. Future studies are also needed to
elaborate the mechanisms of anemia in
patientswithdiabetesandCKDincluding
the role of iron metabolism, inﬂamma-
tion, and resistance.
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